Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer

  • Oncologist. 2017 Apr;22(4):375-e30. doi: 10.1634/theoncologist.2016-0133.
Rocío García-Carbonero  1 ,  Eric van Cutsem  2 ,  Fernando Rivera  3 ,  Jacek Jassem  4 ,  Ira Gore Jr  5 ,  Niall Tebbutt  6 ,  Fadi Braiteh  7 ,  Guillem Argiles  8 ,  Zev A Wainberg  9 ,  Roel Funke ,  Maria Anderson ,  Bruce McCall ,  Mark Stroh ,  Eric Wakshull ,  Priti Hegde ,  Weilan Ye ,  Daniel Chen ,  Ilsung Chang ,  Ina Rhee ,  Herbert Hurwitz  10
Affiliations
  • 1. Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain.
  • 2. UZ Leuven Oncologie, Leuven, Belgium.
  • 3. Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • 4. Medical University of Gdansk, Gdansk, Poland.
  • 5. Birmingham Hematology Oncology Associates, LLC, Birmingham, Alabama, USA.
  • 6. Austin Health, Medical Oncology, Heidelberg, Victoria, Australia.
  • 7. Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, USA.
  • 8. Hospital Universitario Vall d'Hebron, Departamento de Oncología, Barcelona, Spain.
  • 9. University of California, Los Angeles, Los Angeles, California, USA.
  • 10. Duke Clinical Research Institute, Durham, North Carolina, USA [email protected].
PMID: 28275117 DOI: 10.1634/theoncologist.2016-0133
Products